Our lead programs are focused on the treatment of solid tumor malignancies and hematologic malignancies. We achieve this by utilizing our recombinant protein-based platform called iCAR to generate chimeric antigen receptor (CAR) NK cells or T cells within the patient’s body. To gain a better understanding of our process, we invite you to watch our video.
Our iCAR protein is designed with a modular structure, enabling the easy generation of a wide range of iCAR proteins for treating various diseases, including cancer, autoimmune, inflammatory, and cardiovascular conditions. Moreover, our modular protein can be applied to stem cell-mediated regenerative medicine through the in vivo hybrid-allosteric receptor (iHAR) approach. By simply switching the required modules, we can induce stem cells to express HAR.
Both iCAR and iHAR consist of effector cell targeting domains (for immune cells or stem cells), disease cell targeting domains, and signal-inducer domains. iCAR stimulates immune cells to attack cancer cells, while iHAR triggers the trans-differentiation of HAR-stem cells into the desired cell types.
Compared to gene-based therapies, recombinant proteins offer advantages such as rapid activity, predictable dosing, and reliable stability.